来自困境社区的患者在血管腔内动脉瘤修复时更可能有症状,且长期随访丢失风险增加
研究利用血管外科学会血管质量倡议数据库,分析2003至2021年接受EVAR的60972例患者,按困境社区指数(DCI)>60与≤60分组。DCI>60组更可能有症状性AAA(11.1% vs 7.9%),30天死亡风险更高(aOR 3.98),1年死亡风险更高(aOR 1.74),随访丢失率更高(28.9% vs 26.3%)。
要点
- DCI>60组有症状性AAA比例更高(11.1% vs 7.9%,aOR 1.25)。
- DCI>60组30天死亡风险更高(aOR 3.98,95%CI 2.23-5.44)。
- DCI>60组1年死亡风险更高(aOR 1.74,95%CI 1.43-2.13)。
核心结论
- 来自困境社区需EVAR的患者倾向于有多种合并症,更可能因有症状AAA接受治疗且死亡风险更高,长期随访丢失发生率也更高。
- 作者认为外科医生和医疗系统应考虑这些结果并采取以患者为中心的方法以确保公平医疗。
研究设计与样本
- 使用血管外科学会血管质量倡议数据库,选取2003至2021年接受EVAR的患者进行分析。
- 按DCI评分分组:DCI 61-100为I组(DCI>60),DCI 0-60为II组(DCI≤60)。
- 共纳入60972例患者,其中I组18549例(30.4%),II组42423例(69.6%);女性19.5%,男性80.5%;平均年龄73±8.9岁。
主要发现
- I组较II组更年轻(平均年龄72.6 vs 73.7岁),体重不足比例更高(3.5% vs 2.5%),非裔美国人比例更高(10.8% vs 3.5%),医疗补助保险比例更高(3.6% vs 1.9%)(P均<.05)。
- I组较II组吸烟者更多(87.3% vs 85.3%),合并症比例更高:高血压(84.5% vs 82.9%)、糖尿病(21.7% vs 19.7%)、冠心病(30.3% vs 28.6%)、慢性阻塞性肺疾病(36.9% vs 31.8%)、中重度充血性心力衰竭(2.6% vs 2%)(P均<.05)。
- I组较II组更可能因有症状AAA接受EVAR(11.1% vs 7.9%;P<.001;aOR 1.25;95%CI 1.15-1.37;P<.001)。
- I组较II组30天死亡风险更高(aOR 3.98;95%CI 2.23-5.44;P<.001),1年死亡风险更高(aOR 1.74;95%CI 1.43-2.13;P<.001)。
- I组较II组随访丢失风险更高(28.9% vs 26.3%;P<.001)。
临床怎么用
- 作者认为外科医生和医疗系统应考虑这些结果并采取以患者为中心的方法以确保公平医疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular aortic aneurysm repair (EVAR) has become the preferred modality to repair abdominal aortic aneurysms (AAAs). However, the effect of the distressed communities index (DCI) on the outcomes of EVAR is still unknown. In the present study, we investigated the effect of DCI on the postoperative outcomes after EVAR. METHODS: The Society for Vascular Surgery Vascular Quality Initiative database was used for the present study. Patients who had undergone EVAR from 2003 to 2021 were selected for analysis. The study cohort was divided into two groups according to their DCI score. Patients with DCI scores ranging from 61 to 100 were assigned to group I (DCI >60), and those with DCI scores ranging from 0 to 60 were assigned to group II (DCI ≤60). The primary outcomes included the 30-day and 1-year mortality and major adverse cardiovascular events at 30 days. Regression analyses were performed to study the postoperative outcomes. P values ≤ .05 were deemed statistically significant for all analyses in the present study. RESULTS: A total of 60,972 patients (19.5% female; 80.5% male) had undergone EVAR from 2003 to 2021. Of these patients, 18,549 were in group I (30.4%) and 42,423 in group II (69.6%). The mean age of the study cohort was 73 ± 8.9 years. Group I tended to be younger (mean age, 72.6 vs 73.7 years), underweight (3.5% vs 2.5%), and African American (10.8% vs 3.5%) and were more likely to have Medicaid insurance (3.6% vs 1.9%; P < .05 for all). Group I had had more smokers (87.3% vs 85.3%), a higher rate of comorbidities, including hypertension (84.5% vs 82.9%), diabetes (21.7% vs 19.7%), coronary artery disease (30.3% vs 28.6%), chronic obstructive pulmonary disease (36.9% vs 31.8%), and moderate to severe congestive heart failure (2.6% vs 2%; P < .05 for all). The group I patients were more likely to undergo EVAR for symptomatic AAAs (11.1% vs 7.9%; P < .001; adjusted odds ratio [aOR], 1.25; 95% confidence interval [CI], 1.15-1.37; P < .001) with a higher risk of mortality at 30 days (aOR, 3.98; 95% CI, 2.23-5.44; P < .001) and 1 year (aOR, 1.74; 95% CI, 1.43-2.13; P < .001). A higher risk of being lost to follow-up (28.9% vs 26.3%; P < .001) was also observed in group I. CONCLUSIONS: Patients from distressed communities who require EVAR tended to have multiple comorbidities. These patients were also more likely to be treated for symptomatic AAAs, with a higher risk of mortality. An increased incidence of lost to long-term follow-up was also observed for this population. Surgeons and healthcare systems should consider these outcomes and institute patient-centered approaches to ensure equitable healthcare.
引用
- Radtka JF, Zil-E-Ali A, Medina D, et al. Patients from distressed communities are more likely to be symptomatic at endovascular aneurysm repair and have an increased risk of being lost to long-term follow-up. J Vasc Surg. 2022. PMID: 36343872. doi:10.1016/j.jvs.2022.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。